泰林生物
(300813)
| 流通市值：19.55亿 | | | 总市值：31.15亿 |
| 流通股本：7605.11万 | | | 总股本：1.21亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 148,853,721.98 | 149,088,376.64 | 134,971,542.57 | 197,925,160.45 |
| 交易性金融资产 | 80,100,000 | 61,120,441.21 | 2,100,542.69 | - |
| 应收票据及应收账款 | 47,105,838.29 | 55,073,932.77 | 49,034,637.68 | 46,920,018.79 |
| 应收账款 | 47,105,838.29 | 55,073,932.77 | 49,034,637.68 | 46,920,018.79 |
| 应收款项融资 | 17,202,098.35 | 12,778,553.43 | 8,670,714.63 | 7,553,636.6 |
| 预付款项 | 3,545,706.44 | 4,101,853.88 | 6,024,733.49 | 2,653,475.16 |
| 其他应收款合计 | 6,028,789.06 | 7,403,136.38 | 9,377,913.27 | 11,521,981.36 |
| 存货 | 133,422,928.06 | 126,535,071.63 | 153,639,950.2 | 141,538,974.71 |
| 合同资产 | 5,929,333 | 4,967,260.85 | 4,217,771.55 | 8,118,693.85 |
| 其他流动资产 | 109,860,732.37 | 128,781,141.12 | 177,154,730.6 | 173,540,322.44 |
| 流动资产合计 | 552,049,147.55 | 549,849,767.91 | 545,192,536.68 | 589,772,263.36 |
| 非流动资产: | | | | |
| 其他债权投资 | 45,543,997.26 | 55,452,627.4 | 55,263,397.26 | - |
| 长期股权投资 | 10,546,523.82 | 10,549,721.85 | 8,381,997.62 | 8,139,174.06 |
| 投资性房地产 | 8,475,432.25 | 8,551,355.56 | 8,627,278.81 | 8,703,202.05 |
| 固定资产 | 247,514,853.54 | 250,792,052.78 | 253,432,110.02 | 255,722,393.94 |
| 在建工程 | 16,363,513.83 | 9,259,817.63 | 5,161,172.41 | 6,325,657.78 |
| 无形资产 | 27,193,563.16 | 27,392,503.39 | 27,715,686.1 | 11,535,722.92 |
| 长期待摊费用 | 28,933,750.62 | 29,069,749.33 | 29,939,755.76 | 30,562,659.62 |
| 递延所得税资产 | 169,460.81 | 169,460.81 | 233,563.67 | 40,152.68 |
| 其他非流动资产 | 10,117,100 | 17,885,526.73 | 116,267.61 | 16,026,600 |
| 非流动资产合计 | 394,858,195.29 | 409,122,815.48 | 388,871,229.26 | 337,055,563.05 |
| 资产总计 | 946,907,342.84 | 958,972,583.39 | 934,063,765.94 | 926,827,826.41 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 15,815,835.34 | 15,858,863.2 | 15,378,794.85 | 15,003,337.38 |
| 应付账款 | 15,815,835.34 | 15,858,863.2 | 15,378,794.85 | 15,003,337.38 |
| 合同负债 | 68,573,213.04 | 65,727,476.61 | 85,515,627.35 | 73,214,300.59 |
| 应付职工薪酬 | 14,172,051.5 | 28,000,225.11 | 16,597,378.64 | 14,116,617.79 |
| 应交税费 | 4,699,163.32 | 5,069,396.07 | 1,640,570.62 | 2,190,838.53 |
| 其他应付款合计 | 27,715,300.95 | 30,935,912.34 | 17,920,205.44 | 6,327,862.86 |
| 其他流动负债 | 6,937,920.95 | 6,543,946.12 | 3,641,459.24 | 2,705,937.36 |
| 流动负债合计 | 137,913,485.1 | 152,135,819.45 | 140,694,036.14 | 113,558,894.51 |
| 非流动负债: | | | | |
| 递延所得税负债 | 2,545,336.65 | 2,545,336.65 | 3,225,150.58 | 3,054,070.83 |
| 非流动负债合计 | 2,545,336.65 | 2,545,336.65 | 3,225,150.58 | 3,054,070.83 |
| 负债合计 | 140,458,821.75 | 154,681,156.1 | 143,919,186.72 | 116,612,965.34 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 121,199,219 | 121,199,219 | 121,199,219 | 121,199,219 |
| 资本公积 | 413,456,193.44 | 412,503,433.9 | 411,261,023.32 | 409,249,442.39 |
| 减:库存股 | - | - | 11,174,000 | - |
| 盈余公积 | 27,628,568.73 | 27,628,568.73 | 27,628,568.73 | 27,628,568.73 |
| 未分配利润 | 244,164,539.92 | 242,960,205.66 | 241,229,768.17 | 252,137,630.95 |
| 归属于母公司股东权益合计 | 806,448,521.09 | 804,291,427.29 | 790,144,579.22 | 810,214,861.07 |
| 少数股东权益 | - | - | - | 0 |
| 股东权益合计 | 806,448,521.09 | 804,291,427.29 | 790,144,579.22 | 810,214,861.07 |
| 负债和股东权益合计 | 946,907,342.84 | 958,972,583.39 | 934,063,765.94 | 926,827,826.41 |
| 公告日期 | 2026-04-30 | 2026-03-27 | 2025-10-27 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |